Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Chief Development Officer | October 15, 2021 | February 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date October 15, 2021 · Filed February 09, 2022
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2022 Filed Feb 4, 2022 20:16 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 200,000 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001493152-22-003206 · ownership.xml · derivative · entry 1 Pestano Linda · CIK 0001892759 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-04 F1 · security: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · price: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · derivative.exercise_date: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.